"I am interested in reviving (talks), but we want answers too," she told reporters here.
Expressing disappointment and concern over EU's banning the sale of around 700 pharma products clinically tested by GVK Biosciences, India last month deferred talks with the EU on the proposed the Broad-based Investment and Trade Agreement (BTIA).
Sitharaman said India took the decision very much "unilaterally" but after quite a lot of thought on it and added it was India which had emphasised that the chief negotiators should meet at the earliest so that FTA with EU will move forward.
"... But none of that (efforts) had resulted in complete explanatory position of the EU as to what warranted the banning of drugs on which there is no question about the security, safety of the drugs per se," She said.
Also Read
She further said the senior officials too engaged with the EU in a very detailed way.
She questioned EU's unilateral step to ban drugs without replying to India's queries on the Indian sector, saying it has established is internationally acceptable quality for providing life saving drugs at affordable price.
"I thought India's USP, India's brand and India's strength was being questioned" by their action, she added.
Further replying on the issues to be discussed in the first meeting of 'Strategic & Commercial Dialogue' on September 22 with the US, Sitharaman said greater market access, visa liberalisation and non-tariff barriers would come up among other matters.